Study 9 of 23Vipivotide literatureScience (New York, N.Y.)Top journal2021
SARS-CoV-2 dependence on host pathways.
Not reported in abstract.
Where it sits
this study against the rest of the vipivotide corpus3
Preclinical · this one
14
Observational
1
Open-label
3
Randomised
2
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2021
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Vipivotide corpus
BTargeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · n=27 · RP2D for 177Lu-FAP-2286 monotherapy determined to be 9.25 GBq.HumanBOverall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023 · n=140 · Median OS: [177Lu]Lu-PSMA I&T: 14 mo; [177Lu]Lu-PSMA-617: 15 mo; hazard ratio, 1.18; 95% CI, 0.79-1.78; P = 0.42.HumanBReal-world outcomes of [<sup>177</sup>Lu]Lu-PSMA-I&T in [<sup>18</sup>F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.European journal of nuclear medicine and molecular imaging · 2026 · n=25 · PSA30 response in 44% of patients.HumanBEffects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results.European journal of nuclear medicine and molecular imaging · 2026 · n=50 · 2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq for [177Lu]Lu-PSMA-617, p=0.24HumanALutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.European journal of nuclear medicine and molecular imaging · 2026 · n=12 · MTD established at 1000 mg/m².HumanBEvaluation of [<sup>225</sup>Ac]Ac-PSMA-617 vis-a-vis Rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.The Prostate · 2026 · n=66 · PSA decline of >50% and disease control rate of 60% in [225Ac]Ac-PSMA-617 patients.Human